Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.
Pulmonary infiltrates in neutropenic hosts with invasive pulmonary aspergillosis are caused by vascular invasion, hemorrhagic infarction, and tissue necrosis. Monitoring the dynamics of pulmonary infiltrates of invasive aspergillosis is an important tool for assessing response to antifungal therapy. We, therefore, introduced a multidimensional volumetric imaging (MDVI) method for analysis of the response of the volume of pulmonary infiltrates over time to antifungal therapy in experimental invasive pulmonary aspergillosis (IPA) in persistently neutropenic rabbits. We developed a semiautomatic method to measure the volume of lung lesions, which was implemented as an extension of the MEDx visualization and analysis software using ultrafast computerized tomography (UFCT). Volumetric infiltrate measures were compared with UFCT reading, histopathological resolution of lesions, microbiological clearance of Aspergillus fumigatus, and galactomannan index (GMI). We also studied the MDVI method for consistency and reproducibility in comparison to UFCT. Treatment groups consisted of deoxycholate amphotericin B (DAMB) at 0.5 or 1 mg/kg of body weight/day and untreated controls (UC). Therapeutic monitoring of pulmonary infiltrates using MDVI demonstrated a significant decrease in the infiltrate volume in DAMB-treated rabbits in comparison to UC (P<or=0.001). Volumetric data by MDVI correlated with conventional CT pulmonary scores (r=0.83, P<or=0.001). These results correlated with validated biological endpoints: pulmonary infarct scores (r=0.85, P<or=0.001), lung weights (r=0.76, P<or=0.01), residual fungal burden (r=0.65, P<or=0.05), and GMI (r=0.78, P<or=0.01). MDVI correlated with key biological markers, improved the objectivity of radiological assessment of therapeutic response to antifungal therapy, and warrants evaluation for monitoring therapeutic response in immunocompromised patients with invasive aspergillosis.
Petraitis
Vidmantas
V
Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Building 10, CRC, Rm. 1W-5740, 10 Center Dr., MSC 1100, Bethesda, MD 20892-1100, USA.
Petraitiene
Ruta
R
Solomon
Jeffrey
J
Kelaher
Amy M
AM
Murray
Heidi A
HA
Mya-San
Christine
C
Bhandary
Avi K
AK
Sein
Tin
T
Avila
Nilo A
NA
Basevicius
Algidas
A
Bacher
John
J
Walsh
Thomas J
TJ
D000666:Amphotericin B / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D003840:Deoxycholic Acid / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology*; D008172:Lung Diseases, Fungal / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D011817:Rabbits; D014057:Tomography, X-Ray Computed
D000935:Antifungal Agents; D004338:Drug Combinations; D003840:Deoxycholic Acid; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination